Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 1366 publications.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pizzi L, Earnshaw S, Blanchette C, Thompson D. Climbing the HEOR career ladder: strategies for success in an era of change. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ. Advanced patient-reported outcomes. Mastering Patient-Reported Outcomes (PRO) in Drug Development. Presentation to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada. Previously presented at the ISPOR Europe 2024.

Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, Yoshikawa-Ryan K, Kovesdy CP, Vizcaya D, Kashihara N. Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-a hospital-based cohort study in Japan. Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16394

Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762

Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8

La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057

La EM, Sweeney C, Davenport E, Calhoun S, Harmelink A, Singer D. Healthcare professionals' knowledge, attitudes, and practices regarding respiratory syncytial virus disease and vaccination in adults aged 60 years and older. Infect Dis Ther. 2025 Apr;14(4):735-52. doi: 10.1007/s40121-025-01119-0

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease. Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006

Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer. Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719

Zubizarreta-Arruti U, Bosch R, Soler Artigas M, Cabana-Dominguez J, Llonga N, Carabi-Gassol P, Macias-Chimborazo V, Vilar-Ribo L, Ramos-Quiroga JA, Pagerols M, Prat R, Rivas C, Pagespetit E, Puigbo J, Espanol-Martin G, Raimbault B, Valentin A, Sunyer J, Foraster M, Gascon M, Casas M, Ribases M, Alemany S. Associations between air pollution and surrounding greenness with internalizing and externalizing behaviors among schoolchildren. Child Adolesc Ment Health. 2025 Mar 21. doi: 10.1111/camh.12772

Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289

Aguilar-Lacasana S, Cosin-Tomas M, Raimbault B, Gomez-Herrera L, Sanchez O, Zanini MJ, Capdevila RP, Foraster M, Gascon M, Rivas I, Llurba E, Gomez-Roig MD, Sunyer J, Bustamante M, Vrijheid M, Dadvand P. Epigenome-wide association study of pregnancy exposure to green space and placental DNA methylation. Environ Res. 2025 Mar 4;274:121286. doi: 10.1016/j.envres.2025.121286

Barrett AM, Olayinka-Amao O, Martin S, Doshi D, Bishop KM, Youakim JM. Assessing experiences with trofinetide for rett syndrome: interviews with caregivers of participants in clinical trials. Clin Ther. 2025 Mar;47(3):181-8. doi: 10.1016/j.clinthera.2024.12.012

Silver SM, Houghton K, Hitchens A, Ansquer VD, Ciepielewska M. Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria. J Dermatol. 2025 Mar;52(3):416-22. doi: 10.1111/1346-8138.17607

Hill NL, Bhargava S, Do J, Bratlee-Whitaker EM, Brown MJ, Komalasari R, Wu R, Mogle J. Just as expected? Older adults' aging expectations are associated with subjective cognition. Aging Ment Health. 2025 Mar 1;29(3):444-51. doi: 10.1080/13607863.2024.2399080

Paller AS, Siegfried EC, Marron SE, Clark M, Harris N, Kosa K, Qin S, Whalley D, Chao J, Bansal A, Chuang CC, Wang Z. Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis. J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e209-12. doi: 10.1111/jdv.20199

Khanji C, Nuabor W, Gould T, Kim HK, Barrows S, Herbel B, Njue A. Systematic literature review of outcomes associated with adherence to haemophilia drug therapy. Haemophilia. 2025 Mar;31(2):187-206. doi: 10.1111/hae.15153

Naik H, Brown M, Meninger S, Lombardelli S. Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study. Mol Genet Metab Rep. 2025 Mar;42:101174. doi: 10.1016/j.ymgmr.2024.101174

Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, Zhou J, Bennett L, Anthony MS. A comparative real-world study evaluating the safety of immune globulin infusion (human) 10% solution and other intravenous immunoglobulin therapies for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Pharmacoepidemiol Drug Saf. 2025 Mar;34(3):e70124. doi: 10.1002/pds.70124

Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, Olopoenia A, DeCongelio M, Maculaitis MC, Zhou X. Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data. Kidney Med. 2025 Feb 27;7(5):100988. doi: 10.1016/j.xkme.2025.100988

Murillo ER, Mora JRM, Bachiller MM, Santiago LG, Braque NN, Bravo MO. Factors associated with low adherence to inhaled therapy in patients with chronic respiratory diseases: a cross-sectional study. BMC Pulm Med. 2025 Feb 27;25(1):94. doi: 10.1186/s12890-025-03563-7.

Frederiksen KS, Hahn-Pedersen J, Crawford R, Morrison R, Jeppesen R, Doward L, Weidner W. Traversing shifting sands-the challenges of caring for someone with Alzheimer's disease and the impact on care partners: social media content analysis. J Med Internet Res. 2025 Feb 18;27:e55468. doi: 10.2196/55468

Pritchard C, Kutikova L, Pitman R, Lai KZH, Beyhaghi H, Gibbons I, Erbe A, Zivkovic-Gojovic M, Cosgrove C, Sculpher M, Salisbury D. Cost-effectiveness of introducing nuvaxovid to COVID-19 vaccination in the United Kingdom: a dynamic transmission model. Vaccines (Basel). 2025 Feb 14;13(2):187. doi: 10.3390/vaccines13020187

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Chen ST, Katzka DA. Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis: results of a web-based survey in the United States. J Clin Gastroenterol. 2025 Feb;59(2):138-46. doi: 10.1097/MCG.0000000000002006

Pathak A, Weber MA, Poulos C, Cohen SA, DeBruin V, Kandzari DE. Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment. J Hypertens. 2025 Feb 1;43(2):228-35. doi: 10.1097/HJH.0000000000003872

Patel JN, Chaihorsky L, Dong OM, Lu CY, Moretz C, Reese E, Teeple W, Brown B, Rogers S. Medical policy determinations for pharmacogenetic tests among US health plans. Am J Manag Care. 2025 Feb 1;31(2):e47-55. doi: 10.37765/ajmc.2025.89683

Barrett A, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P. A plain language summary of a study exploring the experiences of people with relapsing-remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better? Neurodegener Dis Manag. 2025 Feb;15(1):9-16. doi: 10.1080/17582024.2024.2441068

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457

Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18–35 years: a pooled database analysis. Kidney Med. 2025 Jan;7(1):100935. doi: 10.1016/j.xkme.2024.100935

Halsby K, Dobler G, Easton A, Karelis G, Krbkova L, Kyncl J, Sellner J, Strle F, Veje M, Zajkowska J, Zavadska D, Angulo FJ, Pilz A, Erber W, Gabriel M, Russo J, Price M, Madhava H, Meyding-Lamade UK. Evaluating the need for standardised disease manifestation categories in patients infected with the tick-borne encephalitis virus: a Delphi panel. Ticks Tick Borne Dis. 2025 Jan;16(1):102431. doi: 10.1016/j.ttbdis.2024.102431

Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs. Expert Rev Vaccines. 2024 Dec 31;23(1):879-86. doi: 10.1080/14760584.2024.2409662

Cappellini MD, Glassberg MB, Meyers J, Jimenez M, Nham T, Bueno L, Sieluk J, Yucel A, Alashkar F. Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study. Ther Adv Hematol. 2024 Dec 15;15. doi: 0.1177/20406207241298088

Pistillo A, Warkentin S, Abellan A, de Bont J, Ranger T, Perez-Crespo L, Cirach M, Perramon-Malavez A, Khalid S, Nieuwenhuijsen M, Vrijheid M, Duarte-Salles T. Residential relocation and changes in patterns of environmental exposures by health determinants among children and adolescents in Catalonia, Spain. Environ Res. 2024 Dec 15;263(Pt 2):120152. doi: 10.1016/j.envres.2024.120152

Ismail Z, Meehan SR, Farovik A, Miguelez M, Kapadia S, Regnier SA, Zhang Z, Brown TM, Milien M, McIntyre RS. Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale. Schizophr Res. 2024 Dec;274:337-44. doi: 10.1016/j.schres.2024.10.008

Barbieri M, Talbird S, Carrico J, Boccalini S, Bencina G, Bonanni P, Mellott CE, Senese F, Lang JC, Bechini A. Public health impact and return on investment of the pediatric National Immunization Program in Italy. Expert Rev Vaccines. 2024 Dec;23(1):974-85. doi: 10.1080/14760584.2024.2411425

D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623

DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Dec;46(12):1016-23. doi: 10.1016/j.clinthera.2024.09.010

Chuang CC, Pariser DM, Simpson E, Dine J, Brown M, Fehnel S, Wang Z. The atopic dermatitis control tool: adaptation and content validation for children and caregivers of children with atopic dermatitis. Dermatol Ther. 2024 Dec;14(12):3261-71. doi: 10.1007/s13555-024-01289-8

Howard K, Adelman D, Ghura S, Acaster S, Clifford S, Kelly CP, Martin SA, Meckley LM, Leffler DA. Development of the celiac disease symptom diary version 2.1© (CDSD 2.1©) patient-reported outcome measure. Qual Life Res. 2024 Dec;33(12):3275-82. doi: 10.1007/s11136-024-03799-6

Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Dec;13(12):2527-43. doi: 10.1007/s40121-024-01064-4

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States. J Alzheimers Dis. 2024 Dec;102(4):1260-70. doi: 10.1177/13872877241297361